CH Biotech R&D Co., Ltd.

TWSE:6534 Stock Report

Market Cap: NT$8.6b

CH Biotech R&D Management

Management criteria checks 2/4

CH Biotech R&D's CEO is Cho-Chun Huang, appointed in Sep 2021, has a tenure of 3.33 years. directly owns 0.035% of the company’s shares, worth NT$3.02M. The average tenure of the management team and the board of directors is 6.2 years and 3.3 years respectively.

Key information

Cho-Chun Huang

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure3.3yrs
CEO ownership0.04%
Management average tenure6.2yrs
Board average tenure3.3yrs

Recent management updates

Recent updates

CH Biotech R&D (GTSM:6534) Takes On Some Risk With Its Use Of Debt

Apr 05
CH Biotech R&D (GTSM:6534) Takes On Some Risk With Its Use Of Debt

A Look At CH Biotech R&D's (GTSM:6534) Share Price Returns

Mar 18
A Look At CH Biotech R&D's (GTSM:6534) Share Price Returns

Are CH Biotech R&D Co., Ltd.'s (GTSM:6534) Mixed Financials The Reason For Its Gloomy Performance on The Stock Market?

Feb 09
Are CH Biotech R&D Co., Ltd.'s (GTSM:6534) Mixed Financials The Reason For Its Gloomy Performance on The Stock Market?

Returns On Capital At CH Biotech R&D (GTSM:6534) Paint An Interesting Picture

Jan 11
Returns On Capital At CH Biotech R&D (GTSM:6534) Paint An Interesting Picture

Does CH Biotech R&D (GTSM:6534) Have A Healthy Balance Sheet?

Dec 15
Does CH Biotech R&D (GTSM:6534) Have A Healthy Balance Sheet?

Tread With Caution Around CH Biotech R&D Co., Ltd.'s (GTSM:6534) 1.8% Dividend Yield

Nov 24
Tread With Caution Around CH Biotech R&D Co., Ltd.'s (GTSM:6534) 1.8% Dividend Yield

CEO

Cho-Chun Huang

3.3yrs

Tenure

Ms. Cho-Chun Huang serves as the President at CH Biotech R&D Co., Ltd. since September 1, 2021. She was Chief of R&D Department at CH Biotech R&D Co., Ltd.since December 17, 2019 until June 1, 2021. Ms. H...


Leadership Team

NamePositionTenureCompensationOwnership
Cho-Chun Huang
President3.3yrsno data0.035%
NT$ 3.0m
Hsiu-Feng Lin
Assistant Vice President of Finance Department7.3yrsno datano data
Xinjun Luo
Accounting Supervisorno datano datano data
Mu-Sheng Lin
Chief of Board Office7.3yrsno data0.056%
NT$ 4.8m
Kuei-Chun Li
Head of R&D Department5.1yrsno datano data

6.2yrs

Average Tenure

Experienced Management: 6534's management team is seasoned and experienced (6.2 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Cheng-Pang Wu
Chairman11.2yrsno data20.62%
NT$ 1.8b
Chao-Tsung Chiu
Director6.6yrsno data0.15%
NT$ 13.0m
Yung Ming Chou
Director4.3yrsno datano data
Yong-Xiang Chiu
Independent Director3.3yrsno datano data
Robert James Christopher Clayton
Institutional Director1.7yrsno datano data
Wanyu Liu
Independent Directorno datano datano data
Yin-Hsiang Chou
Independent Directorno datano datano data
Jesse Wu
Directorless than a yearno data0.011%
NT$ 918.5k
Wei-Tun Yeh
Directorless than a yearno datano data

3.3yrs

Average Tenure

Experienced Board: 6534's board of directors are considered experienced (3.3 years average tenure).


Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/10 07:12
End of Day Share Price 2025/01/10 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

CH Biotech R&D Co., Ltd. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Yenya KuoCapital Securities Corporation
Hsiu Chi LinMasterlink Securities Corp.